Overview
Lobbying Costs
500,000€ - 599,999€
Financial year: Jan 2021 - Dec 2021
Lobbyists (Full time equivalent)
2 Fte (4)
Lobbyists with EP accreditation
0
High-level Commission meetings
1
Lobbying Costs over the years
-
Info
Biogen Inc. (Biogen)
EU Transparency Register
966165310889-60 First registered on 26 Mar 2013
Goals / Remit
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, neuropsychiatry, and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.
Main EU files targeted
Biogen interacts with EU institutions and engages on issues relevant to Biogen and to the biopharmaceutical sector to develop a healthcare policy environment in which all patients have access to the medicines they need; pharmaceutical treatments are integrated into a continuum of care; financial returns attract investment; and the environment enables us to seek new innovative therapies and hopefully cures for this and future generations. We foster debates around the value of medical innovation including pharmaceutical incentives and rewards, sustainable healthcare systems, the future of neuroscience and patient access inequalities.
In 2021, we monitored several policy and legislative initiatives including the implementation of the EU Pharmaceutical Strategy, debates and initiatives on pricing & access and sustainable health systems and on pharmaceutical incentives & rewards; the implementation of EU Regulations incl. data protection and clinical trials; the adoption of the European proposal on an EU Health Technology Assessment; the review of the OMP and Paediatric Regulations; EU rare disease policies, as well as policies and initiatives related to the use of medicines off-label, the prevention of and early intervention in non-communicable diseases with a focus on neurological diseases, demographic change and healthy ageing, Alzheimer's disease, competition in the pharmaceutical sector.Address
Head Office
225 Binney Street
Cambridge MA 02142
UNITED STATESEU Office
Rue Belliard 40
Bruxelles 1000
BELGIUMWebsite
-
People
Total lobbyists declared
4
Employment time Lobbyists 75% 1 50% 2 25% 1 Lobbyists (Full time equivalent)
2
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 21 Nov 2024
Name Start date End Date Alessandro TEMPRA 26 Nov 2021 26 Nov 2022 Andrea CORAZZA 28 Sep 2021 30 Jul 2022 Andrea CORAZZA 26 Feb 2020 26 Feb 2021 Ms Andreea Antonovici 17 Jan 2020 01 Feb 2021 Alessandro TEMPRA 17 Jan 2020 01 Feb 2021 Ms Isabel KLINNERT 20 Jul 2017 15 Jul 2018 Emanuele DEGORTES 27 Jun 2017 19 Jun 2018 Ms Tresja Bolt 23 Jan 2017 23 Jan 2018 Mr Erwan Gicquel 03 Sep 2015 31 Aug 2016 Ms Danuta Rydlewska 03 Sep 2015 31 Aug 2016 Mr Erwan Gicquel 02 Aug 2014 31 Jul 2015 Ms Danuta Rydlewska 02 Aug 2014 31 Jul 2015 Mr Erwan Gicquel 07 Aug 2013 02 Aug 2014 Ms Danuta Rydlewska 07 Aug 2013 02 Aug 2014 Complementary Information
Only 4 Biogen employees spent more than 10% of their respective work time in 2020 on this.
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Companies & groups
-
Networking
Affiliation
In 2021 Biogen was a member of EFPIA, Eucope and the Alliance for Regenerative Medicines. We are also corporate partners of EU40 - The network of young MEPs and the Institute of Competitiveness (I-COM).
Member organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2021 - Dec 2021
Lobbying costs for closed financial year
500,000€ - 599,999€
Major contributions in closed year
None declared
Intermediaries for closed year
Name Amount incisive health 100,000€ - 199,999€ edelman 0€ - 10,000€ Intermediaries for current year
Name edelman incisive health Closed year Costs
500,000€ - 599,999€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
We have supported the organisation of a number of (virtual) events to raise awarness about key neurological diseases, from MS to Alzheimer's disease to rare neuromuscualr diseases, to which EU policy-makers were invited to speak and attend. To mark Rare Disease day we have launched a campaign entitled #Icare4rare that a number of Members of the European Parliament endorsed. We have also sponsored various articles in EU media outlets, such as Politico, the Parliament Magazine and Euractiv, to raise awarness about policy issues affecting key neurological diseases.
Other activities
None declared
Meetings
Meetings
1 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.
-
Date 27 Nov 2015 Location Brussels Subject Biopharmaceutical industry's contribution to jobs and growth Cabinet Cabinet of Vice-President Jyrki Katainen Portfolio Jobs, Growth, Investment and Competitiveness Attending - Grzegorz Radziejewski (Cabinet member)
Other Lobbyists